Biodesix partners with Thermo Fisher on tumor-naïve MRD blood test program

• Biodesix expanded its MRD strategy through collaborations with Bio-Rad for tumor-informed ctDNA monitoring and Thermo Fisher for a tumor-naïve assay.
• Bio-Rad program uses Droplet Digital PCR to track patient-specific tumor changes in blood, targeting detection below 1 part per million.
• Thermo Fisher program uses Genexus sequencing to detect methylated ctDNA without tumor tissue, widening eligibility for MRD monitoring.
• Both approaches will be validated with investigators at Memorial Sloan Kettering, designed for deployment on partner platforms already installed globally.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodesix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609240600PRIMZONEFULLFEED9832950) on September 24, 2026, and is solely responsible for the information contained therein.